Liquidia develops innovative therapies using its proprietary PRINT® Technology for precise drug particle engineering, which enables the scalable production of uniform drug particles and optimal deposition in the lungs. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Cyborg Score Rationale
The company achieved profitability in the first full quarter of YUTREPIA sales with $51.7 million in net product sales, demonstrating successful commercialization. LQDA exceeded both the US Pharmaceuticals industry (25.2% return) and US Market (12.9% return) over the past year, indicating strong market performance. However, trailing twelve months net income was -$130.4M and operating cash flow was -$93.4M, reflecting early-stage commercialization challenges.
Top Insights
YUTREPIA generated $148.3M in net product sales for 2025 with more than 2,800 unique patient prescriptions since June 2025 launch
Liquidia is developing L606 (liposomal treprostinil inhalation suspension), an investigational sustained-release formulation administered twice-daily via rapid nebulization
LQDA has demonstrated stable share price with low volatility (9% weekly) in the past 3 months compared to market
The company maintains a strong current ratio of 4.43, indicating robust ability to pay short-term obligations
Named Competitors
Treprostinil intravenous/subcutaneous — Established continuous infusion therapy for PAH
Sildenafil/Tadalafil phosphodiesterase inhibitors — Standard oral therapies for pulmonary hypertension
Endothelin receptor antagonists — Alternative class for PAH management
Recent Developments
(Feb 2026) Company to report full year 2025 financial results on March 5, 2026
(Jan 2026) Announced presentation of clinical data across portfolio at Pulmonary Vascular Research Institute 2026 Annual Congress
(Q4 2025) Achieved profitability in first full quarter of YUTREPIA sales with $51.7M in net product sales
Open the full interactive Liquidia Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.